Literature DB >> 9172166

A beta 42 is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury.

S M Gentleman1, B D Greenberg, M J Savage, M Noori, S J Newman, G W Roberts, W S Griffin, D I Graham.   

Abstract

Fatal head injury results in the formation of diffuse parenchymal deposits of amyloid beta-protein (A beta) in the brains of approximately 30% of individuals. We used carboxyl terminal-specific antisera to examine the exact nature of these deposits in paraffin sections of neocortex from seven head-injured patients. Immunostaining for A beta 42 was observed in all parenchymal deposits whereas staining for A beta 40, the form of the protein which predominates in serum and cerebrospinal fluid, was seen in only a small proportion of deposits. The relative paucity of A beta 40 suggests that post-traumatic deposits do not arise as a result of passive leakage from damaged cerebral blood vessels but are similar to the early A beta 42 parenchymal deposits seen in Down's syndrome and Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9172166     DOI: 10.1097/00001756-199704140-00039

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  37 in total

Review 1.  Axonal pathology in traumatic brain injury.

Authors:  Victoria E Johnson; William Stewart; Douglas H Smith
Journal:  Exp Neurol       Date:  2012-01-20       Impact factor: 5.330

2.  Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism.

Authors:  Y M Kuo; T A Kokjohn; M D Watson; A S Woods; R J Cotter; L I Sue; W M Kalback; M R Emmerling; T G Beach; A E Roher
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Newfound effect of N-acetylaspartate in preventing and reversing aggregation of amyloid-beta in vitro.

Authors:  Jean-Pierre Dollé; Jeffrey M Rodgers; Kevin D Browne; Thomas Troxler; Feng Gai; Douglas H Smith
Journal:  Neurobiol Dis       Date:  2018-05-31       Impact factor: 5.996

4.  Detrimental effect of genetic inhibition of B-site APP-cleaving enzyme 1 on functional outcome after controlled cortical impact in young adult mice.

Authors:  Rebekah C Mannix; Jimmy Zhang; Juyeon Park; Christopher Lee; Michael J Whalen
Journal:  J Neurotrauma       Date:  2011-08-29       Impact factor: 5.269

5.  Widespread τ and amyloid-β pathology many years after a single traumatic brain injury in humans.

Authors:  Victoria E Johnson; William Stewart; Douglas H Smith
Journal:  Brain Pathol       Date:  2011-09-12       Impact factor: 6.508

6.  Beta-amyloid deposition in chronic traumatic encephalopathy.

Authors:  Thor D Stein; Philip H Montenigro; Victor E Alvarez; Weiming Xia; John F Crary; Yorghos Tripodis; Daniel H Daneshvar; Jesse Mez; Todd Solomon; Gaoyuan Meng; Caroline A Kubilus; Kerry A Cormier; Steven Meng; Katharine Babcock; Patrick Kiernan; Lauren Murphy; Christopher J Nowinski; Brett Martin; Diane Dixon; Robert A Stern; Robert C Cantu; Neil W Kowall; Ann C McKee
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

7.  Concurrent Mild Traumatic Brain Injury and Posttraumatic Stress Disorder Is Associated With Elevated Tau Concentrations in Peripheral Blood Plasma.

Authors:  Cassandra L Pattinson; Jessica M Gill; Sara M Lippa; Tracey A Brickell; Louis M French; Rael T Lange
Journal:  J Trauma Stress       Date:  2019-07-10

Review 8.  Disordered APP metabolism and neurovasculature in trauma and aging: Combined risks for chronic neurodegenerative disorders.

Authors:  Milos D Ikonomovic; Zhiping Mi; Eric E Abrahamson
Journal:  Ageing Res Rev       Date:  2016-11-06       Impact factor: 10.895

Review 9.  Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease?

Authors:  Victoria E Johnson; William Stewart; Douglas H Smith
Journal:  Nat Rev Neurosci       Date:  2010-05       Impact factor: 34.870

10.  Cerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotype.

Authors:  P D Leclercq; L S Murray; C Smith; D I Graham; J A R Nicoll; S M Gentleman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.